58 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27789138	355	Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.	Abbvie Bioresearch Center
27816515	143	Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.	Merck
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
26270416	70	Discovery of Potent and Selective RSK Inhibitors as Biological Probes.	Novartis Institutes For Biomedical Research
25147152	1	Kaempferol, a potential cytostatic and cure for inflammatory disorders.	Npo-International Laboratory of Biochemistry
24913714	53	Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.	Merck Research Laboratories
25589938	5	Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101.	Northeastern University
25313996	91	Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.	Merck Research Laboratories
24534486	56	2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors.	Novartis Institutes For Biomedical Research
23535330	83	Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.	Merck Research Laboratories
23434140	35	Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.	East China University of Science and Technology
23394126	170	Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).	Exelixis
23519677	8	Improving the affinity of SL0101 for RSK using structure-based design.	Vanderbilt University
22765894	223	The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.	Exelixis
22621397	39	Irreversible protein kinase inhibitors: balancing the benefits and risks.	Covalution Pharma
23103095	125	Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.	Abbott Laboratories
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
22795331	51	Pyrimidinopyrimidine inhibitors of ketohexokinase: exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket.	Janssen Pharmaceutical Companies of Johnson & Johnson
22564207	44	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.	Cephalon
22503250	128	Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity.	Amri
22464132	8	Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability.	University of Virginia
24900346	90	Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site.	TBA
22342124	9	Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.	Exelixis
21128646	88	Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.	Merck Research Laboratories
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
14593182	34	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.	Pfizer
18077425	197	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.	Harvard Medical School
17935989	146	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.	Abbott Laboratories
17350261	16	Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.	Johnson & Johnson Pharmaceutical Research & Development
16876403	85	Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
15999997	85	Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.	Serono Pharmaceutical Research Institute
22100312	70	Indole RSK inhibitors. Part 1: discovery and initial SAR.	Boehringer Ingelheim Pharmaceuticals
22056746	53	Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.	Boehringer Ingelheim Pharmaceuticals
21794960	194	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.	Universit£
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
20674350	63	Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.	Merck Research Laboratories
21488662	18	SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration.	East China University of Science and Technology
21375264	77	Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors	Roche Palo Alto
20855207	26	Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.	Merck Research Laboratories
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
17259979	5	A clickable inhibitor reveals context-dependent autoactivation of p90 RSK.	University of California
19926477	100	2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.	Abbott Laboratories
17166835	12	Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors.	Istituto Di Ricerche Di Biologia Molecolare &Quot;P. Angeletti
15919995	4	Structural bioinformatics-based design of selective, irreversible kinase inhibitors.	University of California
17658776	109	Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.	Abbott Laboratories
17303421	56	Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.	Roche Research Center
15711537	653	A small molecule-kinase interaction map for clinical kinase inhibitors.	Ambit Biosciences
15149684	59	3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.	Johnson & Johnson Pharmaceutical Research & Development
27996267	22	Covalent Modifiers: A Chemical Perspective on the Reactivity of?,?-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.	University of Pittsburgh
20028980	8	Inhibition of AcpA phosphatase activity with ascorbate attenuates Francisella tularensis intramacrophage survival.	University of Florida
17630989	9	Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.	Abbott Laboratories
16249185	8	The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.	Vertex Pharmaceuticals
15755666	18	Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase.	Biocryst Pharmaceuticals